News
Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...
The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...
Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...
Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...
Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.
Sanofi has said “deal” to Chrissy Teigen. The model, cookbook author and “Deal or No Deal” banker has signed on as a ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...
Here is the complete list of companies whose shares will trade ex-date on April 17, 2025, along with their key corporate ...
Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...
Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...
Analysts fell to the sidelines weighing in on Sanofi (SNYNF – Research Report) and HealthStream (HSTM – Research Report) with neutral ratings, ...
Despite 2024 top-line numbers some analysts found disappointing, L’Oréal doubled down on profits, achieving record gross and operating margins. Excluding Aēsop, acquired from Natura&Co. in 2023, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results